Arthur Kavanaugh - Concepedia

Author

Arthur Kavanaugh

Also Known As

A KAVANAUGH, A Kavanaugh, A. Kavanaugh, A. Reynolds, ARTHUR KAVANAUGH, Alex Kavanaugh, Arthur Kavanaugh, E. C. Keystone, E. Keystone, J.-C. Becker

289

Publications

19.5K

Citations

H-Index

Concepts

All Affiliations

University of California San Diego The University of Texas Southwestern Medical Center University of Toronto AbbVie (United States)University of Leeds

About

Arthur Kavanaugh is an author at University of California San Diego specializing in medicine, rheumatology, and rheumatoid arthritis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	24	1.7K
2	Allergy	3	3	733
3	Health Sciences	2	2	210
4	Public Health	2	2	88
5	Epidemiology	2	2	65

Arthur Kavanaugh

Publications

11.8K

Citations

H-Index

Page 1

	Year	Citations
The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double‐blind, placebo‐controlled, dose‐ranging trial Paul Emery, Roy Fleischmann, Anna Filipowicz‐Sosnowska, Arthritis & Rheumatism	2006	1K
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis Philip J. Mease, Iain B. McInnes, Bruce Kirkham, New England Journal of Medicine	2015	723
Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial Christian Antoni, Gerald G. Krueger, Kurt de Vlam, Annals of the Rheumatic Diseases	2005	704
Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial Cem Gabay, Paul Emery, Ronald van Vollenhoven, The Lancet Rheumatoid DisorderRheumatologyAutoimmune DiseaseAllergyPhase 4	2013	664
Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty‐four–week efficacy and safety results of a randomized, placebo‐controlled study Arthur Kavanaugh, Iain B. McInnes, Philip J. Mease, Arthritis & Rheumatism	2009	595
Efficacy and safety of rilonacept (interleukin‐1 trap) in patients with cryopyrin‐associated periodic syndromes: Results from two sequential placebo‐controlled studies Hal M. Hoffman, M. Throne, N. Amar, Arthritis & Rheumatism	2008	572
Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial Josef S Smolen, R. B. M. Landewé, Philip J. Mease, Annals of the Rheumatic Diseases	2008	489
Guidelines for Clinical Use of the Antinuclear Antibody Test and Tests for Specific Autoantibodies to Nuclear Antigens Arthur Kavanaugh, Russell H. Tomar, John D. Reveille, Archives of Pathology & Laboratory Medicine	2000	436
The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: Results from ATTRACT, a multicenter, randomized, double‐blind, placebo‐controlled trial E. William St. Clair, Carrie Wagner, Adedigbo A. Fasanmade, Arthritis & Rheumatism	2002	421
An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis Michael E. Weinblatt, Arthur Kavanaugh, Mark C. Genovese, New England Journal of Medicine	2010	375

Page 1